W David D. Hardy, MD

Clinical Professor of Family Medicine
Keck School of Medicine of the University of Southern California

Disclosure(s): Gilead Sciences: Advisor/Consultant; Merck: Advisor/Consultant; ViiV Healthcare: Advisor/Consultant

Poster(s):

• (P-310) Patient-reported Outcomes of Long-Acting Injectable Cabotegravir Versus Oral PrEP Use for HIV Prevention: Sub-analysis of the AURORA study
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-311) Real-world Persistence to Long-acting Cabotegravir Versus Oral PrEP for HIV Prevention in Participants Using a Digital Health Companion Tool (AURORA Study)
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET